Literature DB >> 23919353

Polypharmacology - foe or friend?

Jens-Uwe Peters1.   

Abstract

Polypharmacology describes the activity of compounds at multiple targets. Current research focuses on two aspects of polypharmacology: (1) unintended polypharmacology can lead to adverse effects; (2) polypharmacology across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects. This perspective reviews these interconnected aspects of polypharmacology. The first part discusses the relevance of polypharmacology for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacological compounds early in the drug discovery process. The second part discusses the advantages of polypharmacology in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing. This perspective aims to provide a balanced view on polypharmacology, which can compromise the safety of drugs, but can also confer superior efficacy.

Entities:  

Mesh:

Year:  2013        PMID: 23919353     DOI: 10.1021/jm400856t

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  103 in total

1.  PDID: database of molecular-level putative protein-drug interactions in the structural human proteome.

Authors:  Chen Wang; Gang Hu; Kui Wang; Michal Brylinski; Lei Xie; Lukasz Kurgan
Journal:  Bioinformatics       Date:  2015-10-26       Impact factor: 6.937

2.  A Near-IR Fluorescent Dasatinib Derivative That Localizes in Cancer Cells.

Authors:  Syed Muhammad Usama; Bosheng Zhao; Kevin Burgess
Journal:  Bioconjug Chem       Date:  2019-04-01       Impact factor: 4.774

3.  Computational studies to predict or explain G protein coupled receptor polypharmacology.

Authors:  Kenneth A Jacobson; Stefano Costanzi; Silvia Paoletta
Journal:  Trends Pharmacol Sci       Date:  2014-11-14       Impact factor: 14.819

4.  BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536.

Authors:  Lijia Chen; Jeremy L Yap; Makoto Yoshioka; Maryanna E Lanning; Rachel N Fountain; Mithun Raje; Jacob A Scheenstra; Jeffrey W Strovel; Steven Fletcher
Journal:  ACS Med Chem Lett       Date:  2015-05-18       Impact factor: 4.345

5.  Binding site characterization - similarity, promiscuity, and druggability.

Authors:  Christiane Ehrt; Tobias Brinkjost; Oliver Koch
Journal:  Medchemcomm       Date:  2019-06-06       Impact factor: 3.597

6.  Scaffold Ranking and Positional Scanning Identify Novel Neurite Outgrowth Promoters with Nanomolar Potency.

Authors:  Hassan Al-Ali; Ginamarie Debevec; Radleigh G Santos; Richard A Houghten; Jennifer C Davis; Adel Nefzi; Vance P Lemmon; John L Bixby; Marc A Giulianotti
Journal:  ACS Med Chem Lett       Date:  2018-09-24       Impact factor: 4.345

7.  Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.

Authors:  Shipeng He; Guoqiang Dong; Zhibin Wang; Wei Chen; Yahui Huang; Zhengang Li; Yan Jiang; Na Liu; Jianzhong Yao; Zhenyuan Miao; Wannian Zhang; Chunquan Sheng
Journal:  ACS Med Chem Lett       Date:  2015-01-14       Impact factor: 4.345

Review 8.  A Double Whammy: Targeting Both Fatty Acid Amide Hydrolase (FAAH) and Cyclooxygenase (COX) To Treat Pain and Inflammation.

Authors:  Rita Scarpelli; Oscar Sasso; Daniele Piomelli
Journal:  ChemMedChem       Date:  2015-10-21       Impact factor: 3.466

Review 9.  Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces.

Authors:  Michela Rosini; Elena Simoni; Anna Minarini; Carlo Melchiorre
Journal:  Neurochem Res       Date:  2014-02-04       Impact factor: 3.996

10.  Exploiting polypharmacology for drug target deconvolution.

Authors:  Taranjit Singh Gujral; Leonid Peshkin; Marc W Kirschner
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.